[Alemtuzumab in multiple sclerosis]
Alcaraz A, Pichon-Riviere A, Augustovski F, García Martí S, Bardach A, Ciapponi A.
Record ID 32018001456
Original Title: Alemtuzumab en esclerosis múltiple
Authors' recommendations: CONCLUSIONS Moderate quality evidence suggests that alemtuzumab, when compared with subcutaneous Interferon Beta-1a or 1b, might reduce the rate of relapse and progression-free survival in relapsing-remitting multiple sclerosis, with a slight increase in the serious adverse events. There is no adequate quality evidence that may allow assessing the effectiveness, safety and costs of alemtuzumab versus other treatment alternatives such as dimethyl fumarate, fingolimod, glatiramer acetate, natalizumab and teriflunomide. No studies of adequate quality assessing the benefits of alemtuzumab in other forms of multiple sclerosis have been found. The Unites States Food and Drug Administration, the European Agency of Medicines, different coverage policies and clinical practice guidelines approve and/or recommend its use in patients with highly active relapsing-remitting multiple sclerosis although sometimes limiting this recommendation to patients who are refractory to other treatments. The Latin American public health sponsors consulted do not cover it, while sponsors from high-income countries do it, but many times limiting its use to patients with relapsing-remitting multiple sclerosis refractory to interferon or glatiramer acetate.
Project Status: Completed
Year Published: 2018
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Drug Therapy
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.